Non-Opioid pain drug tested against standard analgesia for skin cancer surgery
NCT ID NCT07843134
First seen Sep 25, 2026 · Last updated Sep 25, 2026
Summary
Researchers compare suzetrigine, a non-opioid pain medicine, with scheduled acetaminophen plus ibuprofen for pain after skin cancer surgery on the head or neck. Adults having Mohs surgery or wide local excision receive one of the two treatments for 72 hours. The trial measures pain over the first 24 hours and tracks oxycodone use, side effects, and wound healing.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- suzetrigine, a non-opioid pain medicine
- What this could lead to
- If suzetrigine controls pain as well as standard painkillers, it could offer a non-opioid option after skin cancer surgery and reduce reliance on oxycodone.
- What could go wrong
- The trial may show suzetrigine does not match standard analgesia, and it is limited to a specific surgery type and 72 hours of treatment. Side effects, bleeding, and wound-healing problems are monitored.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
About 230 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Apr 2027
An estimate. Start dates often move.
- Expected to finish
-
Jul 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 18 years or older * Biopsy-proven cutaneous malignancy of the head or neck, including melanoma, melanoma in situ, cutaneous squamous cell carcinoma, or basal cell carcinoma, or a biopsy-confirmed precursor lesion to skin cancer requiring excision * Planned treatment by Mohs micrographic surgery or wide local excision * Surgical defect requiring intermediate layered closure, complex closure, adjacent tissue transfer, or full-thickness skin graft * Able to take oral medications * Access to an electronic diary device, or willingness to use a paper backup * Able to provide written informed consent, with English, Hmong, or Somali language materials and interpreter support available Exclusion Criteria: * Contraindication to ibuprofen, including active peptic ulcer disease, history of gastrointestinal bleeding, estimated glomerular filtration rate below 30 mL/min/1.73 m², or NSAID hypersensitivity * Moderate or severe hepatic impairment, defined as Child-Pugh Class B or C * Chronic heavy alcohol use * Known hypersensitivity to acetaminophen * Known hypersensitivity to opioids * Severe untreated obstructive sleep apnea or other respiratory compromise that would make a short course of breakthrough oxycodone unsafe * Concurrent use of a benzodiazepine or other sedative-hypnotic * Concurrent use of a strong or moderate CYP3A inhibitor, or a strong or moderate CYP3A inducer * Regular opioid use in the prior 30 days, meaning opioid use on most days or any standing opioid prescription * Body weight below 50 kg * Prior major bleeding on a nonsteroidal anti-inflammatory drug, or an active bleeding disorder * Pregnancy or breastfeeding * Prior adverse reaction to suzetrigine * Cognitive impairment precluding completion of patient-reported outcomes * Participation in another interventional trial within 30 days * Children * Fetuses * Neonates * Prisoners * Adults lacking capacity to consent or adults with diminished or fluctuating capacity to consent * Employees of the researcher * Students of the researcher * Individuals approached in emergency or acutely stressful settings
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acute pain are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
3 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
M Health Fairview Clinic - Maple Grove
Maple Grove, Minnesota, 55369, United States
-
M Health Fairview Clinic - Wyoming
Wyoming, Minnesota, 55092, United States
-
M Health Fairview Clinics and Surgery Center
Minneapolis, Minnesota, 55455, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common steroid pill curb pain and nausea after knee replacement?
- Half the anesthetic, same pain relief? trial tests lower bupivacaine dose for gallbladder surgery
- Can a direct injection clear skin cancer without surgery?
- Can a 20-Minute massage calm women before breast surgery?
- Epidural or Opioid-Sparing? trial tests which pain plan wins after hernia surgery
- Non-Opioid pain drug tested for hysterectomy recovery